Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BrightGene Bets On Remdesivir Amid Patent Questions

Claims R&D Work Is Non-Infringing

Executive Summary

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

You may also be interested in...



Coronavirus: Can Companies Achieve Vaccine Ambition?

China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene

After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for  Celgene's Abraxane to supply China.

Coronavirus Clash: Global Pharma Scrambles In Locking Down World

A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141667

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel